Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The AIR-BX2 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and
gram-negative airway infection. Participants received two 28-day courses of either Aztreonam
for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a
28-day off-drug period. Following the two blinded courses, all participants received a 28-day
course of open-label AZLI then were followed for an additional 56 days.